In 2024, the global myocardial infarction therapeutics market is valued at around USD 2.5 billion and is expected to reach approximately USD 4.3 billion by 2032. This growth is expected at a compound annual growth rate (CAGR) of about 6.8%. The rise in cardiovascular diseases, better hea